Catalog No.
EHG17601
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Glu141
Predicted molecular weight
16.64 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q08722
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
SIRPalpha-CD47 Immune Checkpoint Blockade in Anticancer Therapy. PMID: 29336991
The CD47-SIRPalpha Immune Checkpoint. PMID: 32433947
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPalpha Axis. PMID: 32082311
The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. PMID: 28258703
CD47: role in the immune system and application to cancer therapy. PMID: 31485984
CD47: the next checkpoint target for cancer immunotherapy. PMID: 32535479
Blocking "don't eat me" signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. PMID: 29709247
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. PMID: 27437576
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. PMID: 26322579
CD47 signaling pathways controlling cellular differentiation and responses to stress. PMID: 25708195
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. PMID: 29994903
Role of CD47 in Hematological Malignancies. PMID: 32677994
Is CD47 an innate immune checkpoint for tumor evasion? PMID: 28077173
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. PMID: 32929084
Just eat it: A review of CD47 and SIRP-alpha antagonism. PMID: 32517874
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. PMID: 22451913
Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. PMID: 31771616
CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development. PMID: 30308165
Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo. PMID: 31676794
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. PMID: 19632179
Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition. PMID: 32576678
Exosome-SIRPalpha, a CD47 blockade increases cancer cell phagocytosis. PMID: 28086180
The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. PMID: 24215318
The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors. PMID: 31686549
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRP axis. PMID: 31183992
CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer. PMID: 27411490
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. PMID: 33389016
The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. PMID: 22310103
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. PMID: 31689243
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. PMID: 32761423
CD47 Blocking Antibody Accelerates Hematoma Clearance After Intracerebral Hemorrhage in Aged Rats. PMID: 31664629
Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment. PMID: 27322955
[Role of CD47 in hematologic malignancies]. PMID: 24370062
Selective CD47 targeting with a bispecific antibody. PMID: 33388996
Anti-CD47 Agent Boosts Macrophage Activity in NHL. PMID: 30464001
CD47 promotes cell growth and motility in epithelial ovarian cancer. PMID: 31493748
The CD47-SIRPalpha signalling system: its physiological roles and therapeutic application. PMID: 24627525
Blocking thrombospondin-1 signaling via CD47 mitigates renal interstitial fibrosis. PMID: 32366943
The use of CD47-modified biomaterials to mitigate the immune response. PMID: 27190273
CD47 checkpoint data supercharge Stanford spinout IPO. PMID: 30080839
Targeting CD47: NO limit on therapeutic potential. PMID: 17363705
CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. PMID: 21191182
Elimination of donor CD47 protects against vascularized allograft rejection in mice. PMID: 30136356
CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. PMID: 29288236
CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. PMID: 18855618
CD47: a new target in cardiovascular therapy. PMID: 18187671
TSP1-CD47-SIRPalpha signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium. PMID: 32196807
CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. PMID: 22774848
CD47 in the Brain and Neurodegeneration: An Update on the Role in Neuroinflammatory Pathways. PMID: 34203368
Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. PMID: 32830120
Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection. PMID: 32294445
The macrophage checkpoint CD47 : SIRPalpha for recognition of 'self' cells: from clinical trials of blocking antibodies to mechanobiological fundamentals. PMID: 31431181
Clinicopathological significance of CD47 expression in hepatocellular carcinoma. PMID: 32576628
Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its management. PMID: 22874763
CD47: a new player in phagocytosis and xenograft rejection. PMID: 21258362
CD47-ligation induced cell death in T-acute lymphoblastic leukemia. PMID: 29748606
Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. PMID: 30938231
CD47 Blockade and Cowpea Mosaic Virus Nanoparticle In Situ Vaccination Triggers Phagocytosis and Tumor Killing. PMID: 30838815
A homogeneous SIRPalpha-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. PMID: 32240171
Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice. PMID: 31996683
A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities. PMID: 32583154
Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma. PMID: 31359339
Inhibited CD47 gene affects the clearance of acute myelogenous leukemia stem cells. PMID: 30565723
CD47 in xenograft rejection and tolerance induction. PMID: 20723199
Combination of CD47 and signal-regulatory protein-alpha constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma. PMID: 32342603
Increased lymphocyte activation and atherosclerosis in CD47-deficient mice. PMID: 31337788
For research use only. Not for human or drug use.
